Sanofi reported yesterday that it had good news from the latest phase III trial with its MS drug, Lemtrada. Lemtrada, you will remember, was the star player in the Genzyme-Sanofi valuation discussion and the main object of the contingent value rights (CVR) ultimately crafted to close the deal.
In the latest news from the clinic, Lemtrada was compared to Merck's Rebif in the treatment of multiple sclerosis and patients showed a 55% reduction in relapse rates over a two-year period. Surprisingly though, the drug fell short in showing a statistically signficant reduction in disability rates. Sanofi still plans to press ahead with filings for regulatory approval in the USA and EU in early 2012. See Fierce Biotech.
Posted by Bruce Lehr July 12th 2011.
Comments